Annual report to shareholders
Open the filing on sec.gov
Lantern Pharma Inc. (LTRN)
Nasdaq: LTRN · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2019
The companyfiscal 2025, as filed
Revenuen/a
Net income-$17.1M+17.6%
Earnings per share$-1.57+18.7%
Operating cash flow-$15.7M+12.0%
Cash$4.4M-41.1%
Debtn/a
Shareholders’ equity$6.5M-69.2%
Shares, diluted10.9M+1.3%
Return on equity-262.0%
The recordfrom its filings
Filings in 202639
Newest filingOct 21 · ARS
Annual reportMar 30, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$200,000
Patents granted2
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$18.7MCash from operations -$14.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Proxy statement
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.